Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 Immunogenicity in Children with Pneumonia in China
NCT05372575Completed
- Sponsor
- Pfizer
- Start
- Aug 2019
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Prevnar 13 in Pneumococcal pneumonia (PP), sponsored by Pfizer. Primary endpoints: Geometric Mean Concentrations (GMCs) of Pneumococcal Immunoglobulin G (IgG) at Day 1, Geometric Mean Titers (GMTs) of Pneumococcal Multiplex Opsonophagocytic Activity (MOPA) at Day 1 and 2 more. Started Aug 2019; status: completed.
02
Drugs
Prevnar 13
03
Conditions
Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT05372575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372575.